Mission Critical: Assessing Pharma's Drivers of Change
Four commercial line executives serve as our jury of peers on what's in store for the future of pharma, and discuss the changing criteria for market success, from drugs to consumer products to vaccines.
Sickle Cell Disease In Three Acts
Ben Comer reports on how new pipeline therapies, public research investments, and a renewed sociopolitical focus are working toward a happier outcome for sickle cell disease patients.
Regional Trends in Bioinnovation Investment
California's Bay Area and the Boston/Cambridge nexus continue to dominate bioinnovation in the US. Pharm Exec looks at the factors contributing to the strategic dominance of these regions.
HBA's Women of the Year 2014
The Healthcare Businesswomen's Association honored three female leaders this year. We take an in-depth look at each winner's background and career-and what factors helped push them to the top of their game.
"Market-Based" Price Controls In India?
Three strategic implications for pharma pricing strategies in India.
Whatever Happened To Faster Reimbursement For Generics In Europe?
The plan to accelerate generic pricing and reimbursement has become another tragic European casualty.
Dividing Lines
Three examples from Pharm Exec's coverage this month show that, in our industry, there are always two sides-at least-to every question.
